Monitor for actual sale on Form 4, but given the small size and former director status, no material price impact is expected. This is a routine liquidity event.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $54.31entry
- T+1 · 6mo ago −2.63%α −2.86% · $52.88
- T+5 · 6mo ago −7.88%α −9.35% · $50.03
- T+20 · 5mo ago −12.65%α −12.67% · $47.44
- T+60 · 3mo ago +1.53%α −1.19% · $55.14
Price Chart
How similar events traded
Executive Summary
Former director Paul Sagan filed Form 144 to sell 36,759 shares of Moderna, with an estimated value of ~$2.0 million. The sale is small relative to the company's $19.3B market cap and is routine for a former director.
Key Facts
- Paul Sagan, a former director, intends to sell 36,759 shares of Moderna common stock.
- Estimated aggregate market value of the sale is approximately $2,002,786.
- The sale represents a negligible portion of Moderna's $19.3B market capitalization.
- The filing is an advance notice of intent to sell; the sale may not occur.
Financial Impact
Sale of ~$2.0 million in stock by former director.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-003415 |
| Document: 0001959173-26-003415-index.html | 0001959173-26-003415 |
| Document: 0001959173-26-003415.txt | 0001959173-26-003415 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers